Viral hepatitis B and hepatitis C represent the two most clinically consequential viral infections of the liver, together responsible for the majority of chronic liver disease, cirrhosis, and hepatocellular carcinoma worldwide and generating a combined global mortality burden of approximately 1.3 million deaths annually that places them among the most deadly infectious diseases in human medicine. Despite the availability of a highly effective vaccine for hepatitis B since 1982 and the development of curative antiviral therapy for hepatitis C in 2014, the global burden of viral hepatitis remains enormous, with an estimated 296 million people living with chronic hepatitis B infection and 58 million with chronic hepatitis C infection, the vast majority of whom are unaware of their infection and are therefore untreated and at ongoing risk of progressive liver fibrosis, cirrhosis, and hepatocellular carcinoma. The urgent global public health challenge of viral hepatitis elimination, established as a World Health Organization target for 2030, requires unprecedented scale-up of hepatitis testing, vaccination, and antiviral treatment access across all income settings, addressing the profound inequities in hepatitis care that have allowed these preventable and increasingly treatable infections to continue exacting their devastating toll on populations that lack access to effective interventions.
The natural histories of chronic hepatitis B and hepatitis C infection, while sharing the common trajectory of chronic hepatic inflammation progressing to fibrosis, cirrhosis, and hepatocellular carcinoma over decades of untreated disease, differ in important ways that reflect the distinct virology, immunology, and pathogenesis of these two hepatotropic viruses. Chronic hepatitis B, caused by the hepatitis B virus whose compact partially double-stranded DNA genome integrates into host hepatocyte chromosomal DNA as covalently closed circular DNA that serves as the template for viral transcription and replication, is a lifelong infection whose spontaneous cure is exceedingly rare and whose management therefore focuses on viral suppression rather than elimination of infection. Chronic hepatitis C, caused by the hepatitis C virus whose positive-sense single-stranded RNA genome does not integrate into host DNA, is curable in more than ninety-five percent of treated patients with the direct-acting antiviral regimens developed since 2014, representing one of the most remarkable therapeutic advances in infectious disease medicine and fundamentally transforming the hepatitis C treatment paradigm from indefinite viral suppression to a time-limited curative strategy.
The global distribution of viral hepatitis reflects the diverse transmission routes and the historical determinants of hepatitis prevalence across different world regions. Hepatitis B is hyperendemic in sub-Saharan Africa and East Asia, where vertical transmission from infected mothers to their newborns at birth and horizontal transmission in early childhood from infected household contacts account for the majority of infections and produce the highest rates of chronic infection due to the immature immune tolerance of the neonatal and early childhood period. Hepatitis C is distributed more broadly and is particularly prevalent in Egypt, where a massive iatrogenic transmission event through the widespread use of contaminated syringes for parenteral antischistosomal therapy in the mid-twentieth century produced the world’s highest hepatitis C prevalence, and among people who inject drugs in high-income countries where hepatitis C transmission through shared injection equipment remains the primary route of new infection.
Hepatitis B: Virology, Natural History, and Treatment
The hepatitis B virus, a member of the hepadnavirus family, infects hepatocytes through the binding of its pre-S1 protein to the sodium taurocholate cotransporting polypeptide on the hepatocyte surface, followed by receptor-mediated endocytosis, capsid transport to the nucleus, and the conversion of the relaxed circular DNA genome to covalently closed circular DNA that serves as the episomal template for all viral RNA transcription. The persistence of covalently closed circular DNA in infected hepatocytes, which is not eliminated by currently available antiviral therapies and which can persist even in patients with hepatitis B surface antigen-negative resolved infection, is the primary obstacle to achieving the true virological cure of hepatitis B and explains why current treatment strategies target viral suppression rather than eradication, accepting lifelong treatment in most patients with chronic hepatitis B as the cost of maintaining the viral suppression that prevents fibrosis progression and reduces hepatocellular carcinoma risk.
The natural history of chronic hepatitis B infection follows a dynamic trajectory through distinct immunological phases that reflect the evolving relationship between the host immune response and the replicating virus over the decades of infection. The immune-tolerant phase, characteristic of perinatally acquired infection and lasting from one to three decades, is characterized by very high levels of viral replication with hepatitis B e antigen positivity, very high serum hepatitis B virus DNA concentrations, and minimal hepatic inflammation and fibrosis despite the abundant hepatocyte infection, reflecting the immune tolerance to hepatitis B antigens that is the defining characteristic of neonatal infection. The immune-active or immune-clearance phase follows, characterized by the activation of hepatitis B-specific T lymphocyte responses that partially control viral replication but produce the hepatic inflammation and transaminase elevations that drive progressive fibrosis, and it is during this phase that the highest risk of cirrhosis development occurs. The immune-control or inactive carrier phase, in which hepatitis B e antigen seroconversion to anti-HBe is achieved and viral replication is suppressed to very low levels, carries substantially reduced cirrhosis progression risk but not zero risk of hepatocellular carcinoma due to the integration of viral sequences into host chromosomal DNA at sites that can promote hepatocyte genomic instability.
The antiviral treatment of chronic hepatitis B has been transformed by the development of the nucleoside and nucleotide analogue reverse transcriptase inhibitors entecavir and tenofovir disoproxil fumarate and tenofovir alafenamide, each of which inhibits the hepatitis B virus reverse transcriptase that converts the pre-genomic RNA template to the relaxed circular DNA genome of the virus, suppressing viral replication to below the limit of detection in the vast majority of treated patients within forty-eight to ninety-six weeks of treatment initiation. The high barriers to resistance of both entecavir and tenofovir, reflecting their requirement for multiple simultaneous viral mutations to overcome their inhibitory effects on reverse transcriptase, distinguish them favorably from the earlier nucleoside analogues lamivudine, adefovir, and telbivudine whose lower genetic barriers to resistance produced high rates of viral breakthrough from resistance mutations with long-term treatment. These first-line agents suppress viral replication, reduce hepatic inflammation and fibrosis progression, reduce the risk of hepatic decompensation in cirrhotic patients, and significantly reduce but do not eliminate the risk of hepatocellular carcinoma, establishing indefinite nucleoside analogue therapy as the standard of care for most patients with chronic active hepatitis B who meet treatment criteria.
Hepatitis C: From Diagnosis to Cure
Chronic hepatitis C infection, untreated, follows a characteristic trajectory of progressive hepatic fibrosis that in most individuals spans two to three decades from initial infection to the development of cirrhosis, though with substantial individual variation driven by age at infection, sex, alcohol consumption, obesity, and genetic factors that produce some patients progressing to cirrhosis within ten years and others maintaining minimal fibrosis after thirty years of infection. The clinical silence of hepatitis C during most of this fibrotic progression, with the majority of chronically infected individuals experiencing no or minimal symptoms until hepatic decompensation develops at the cirrhotic stage, explains why an estimated seventy-five percent of the global hepatitis C burden remains undiagnosed and why population-based screening programs targeting birth cohorts with high prevalence are essential for identifying infected individuals before their liver disease has reached an advanced stage.
The direct-acting antiviral therapies for hepatitis C, which specifically inhibit the nonstructural viral proteins NS3/4A protease, NS5A replication complex, and NS5B polymerase that are essential for hepatitis C virus replication, have achieved cure rates defined as sustained virological response twelve weeks after treatment completion of ninety-five to ninety-nine percent across all hepatitis C genotypes in clinical trials and real-world effectiveness studies, using pan-genotypic regimens of eight to twelve weeks duration that are well tolerated and require no ribavirin in most patients. The pan-genotypic combinations of sofosbuvir-velpatasvir and glecaprevir-pibrentasvir, approved for all six hepatitis C genotypes without the need for prior genotype testing in most clinical contexts, have simplified the treatment approach and eliminated the complex genotype-specific regimen selection algorithms that characterized the first generation of direct-acting antivirals, making hepatitis C treatment accessible to the primary care and general internal medicine settings where most infected individuals receive their healthcare.
The achievement of sustained virological response with direct-acting antivirals produces dramatic and durable clinical benefits that extend far beyond the elimination of hepatitis C virus from the circulation. Patients who achieve sustained virological response show significant regression of hepatic fibrosis, with prospective studies demonstrating reductions in fibrosis stage on paired liver biopsy in a substantial proportion of treated patients over the years following viral cure. The risk of hepatocellular carcinoma is reduced by seventy to ninety percent in patients with sustained virological response compared to untreated controls, though the residual hepatocellular carcinoma risk in patients who had established cirrhosis before achieving viral cure requires continued surveillance with regular liver imaging even after successful hepatitis C treatment. Extrahepatic manifestations of hepatitis C infection, including cryoglobulinemic vasculitis, membranoproliferative glomerulonephritis, porphyria cutanea tarda, and the increased cardiovascular and metabolic risks associated with chronic hepatitis C, show improvement or resolution following viral cure, demonstrating the systemic benefits of eliminating hepatitis C infection that extend beyond the hepatic consequences of chronic viral infection.
Prevention and Global Elimination Strategies
The prevention of new hepatitis B infections through vaccination represents one of the most successful and cost-effective public health interventions in medical history, with the recombinant hepatitis B vaccines developed in the 1980s providing greater than ninety percent seroprotection following the standard three-dose primary immunization series and durable protection lasting at least twenty to thirty years in most immunocompetent individuals. The incorporation of hepatitis B vaccination into infant immunization programs in more than one hundred and eighty countries has produced dramatic reductions in hepatitis B surface antigen prevalence in vaccinated birth cohorts, with countries implementing universal neonatal vaccination showing seventy to ninety percent reductions in childhood chronic hepatitis B prevalence compared to prevaccination era rates. The critical additional measure of preventing perinatal hepatitis B transmission from hepatitis B surface antigen-positive mothers to their newborns, through the administration of hepatitis B immune globulin alongside the vaccine birth dose within twelve hours of delivery, achieves ninety to ninety-five percent prevention of mother-to-child transmission when implemented correctly, representing the single most impactful intervention for reducing the global hepatitis B burden in high-prevalence settings.
The WHO Global Health Sector Strategy on Viral Hepatitis 2030, which sets targets of ninety percent reduction in new hepatitis B and C infections and sixty-five percent reduction in hepatitis B and C deaths by 2030, requires the simultaneous scaling up of vaccination, testing, treatment, and harm reduction strategies across all income settings, addressing the profound global inequity in access to hepatitis care that has allowed these infections to disproportionately burden low-income countries where diagnostic and treatment infrastructure is most limited. The declining cost of direct-acting antiviral therapy through generic manufacturing, which has reduced the treatment cost for a full hepatitis C cure from the original cost of eighty-four thousand United States dollars to less than fifty to one hundred dollars in many low-income settings, has transformed the economic feasibility of global hepatitis C elimination and established universal treatment access as a realistic rather than aspirational public health goal for the first time since the direct-acting antiviral era began.